Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.

Participants randomized to first-line tenofovir alafenamide (TAF)/emtricitabine (FTC)+dolutegravir (DTG), tenofovir disoproxil fumarate (TDF)/FTC + DTG, or TDF/FTC/efavirenz (EFV) for 192 weeks were then switched to TDF/lamivudine (3TC)/DTG for 52 weeks. Participants switching either TAF/FTC + DTG or TDF/FTC/EFV to TDF/3TC/DTG showed statistically significant reductions in weight, low-density lipoprotein, triglycerides, glucose and glycated hemoglobin.

Bosch B ，Akpomiemie G ，Chandiwana N ，Sokhela S ，Hill A ，McCann K ，Qavi A ，Mirchandani M ，Venter WDF ... -  《-》

The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir dis

Integrase inhibitors, including dolutegravir (DTG), are associated with weight gain and obesity, especially when combined with tenofovir alafenamide (TAF). Obesity increases the risk of adverse pregnancy outcomes (APOs). This study aimed to predict the risk of APOs caused by treatment-associated obesity, using a hypothetical sample based on the ADVANCE trial. Risk prediction. Firstly, a meta-analysis was performed to determine the relative risk (RR) for APOs in women with obese (≥30) versus normal prepregnancy BMIs (18.5-24.9). For the hypothetical sample, 3000 nonpregnant women with normal BMIs at Week 0 of treatment were evenly allocated across the following treatment arms: TAF/FTC+DTG, TDF/FTC+DTG, TDF/FTC/EFV. The treatment-associated obesity rates from ADVANCE were used to calculate the number of women with obese and normal BMIs expected at Week 96 in our sample. This was combined with the APO RRs to predict the number of women at risk of APOs, in each treatment arm, assuming they conceived at Week 96. At Week 96, the percentage of women predicted to be obese was 14.1% with TAF/FTC+DTG, 7.9% with TDF/FTC+DTG and 1.5% with TDF/FTC/EFV. The RR in women with obese versus normal BMIs was significantly higher for most APOs. Therefore, the number of women at risk of APOs was higher with TAF/FTC+DTG than TDF/FTC+DTG and TDF/FTC/EFV. For example, 11/1000 additional gestational hypertension cases were predicted with TAF/FTC+DTG, 6/1000 with TDF/FTC+DTG and 1/1000 with TDF/FTC/EFV. Treatment-associated obesity increased the APO risk in women. This risk is likely to increase, as preliminary data from ADVANCE demonstrates ongoing weight gain beyond Week 96.

Asif S ，Baxevanidi E ，Hill A ，Venter WDF ，Fairlie L ，Masenya M ，Serenata C ，Sokhela S ，Chandiwana N ... -  《-》

Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.

Colson A ，Chastek B ，Gruber J ，Majethia S ，Zachry W ，Mezzio D ，Rock M ，Anderson A ，Cohen JP ... -  《-》

Weight Changes and Adverse Pregnancy Outcomes With Dolutegravir- and Tenofovir Alafenamide Fumarate-Containing Antiretroviral Treatment Regimens During Pregnancy and Postpartum.

Hoffman RM ，Brummel S ，Ziemba L ，Chinula L ，McCarthy K ，Fairlie L ，Jean-Philippe P ，Chakhtoura N ，Johnston B ，Krotje C ，Nematadzira TG ，Nakayiwa F ，Ndyanabangi V ，Hanley S ，Theron G ，Violari A ，João E ，Correa MD  Jr ，Hofer CB ，Navanukroh O ，Aurpibul L ，Nevrekar N ，Zash R ，Shapiro R ，Stringer JSA ，Currier JS ，Sax P ，Lockman S ，IMPAACT 2010/VESTED Study Team ... -  《-》

Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.

Pozniak AL ，Gallant JE ，DeJesus E ，Arribas JR ，Gazzard B ，Campo RE ，Chen SS ，McColl D ，Enejosa J ，Toole JJ ，Cheng AK ... -  《JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES》